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Independent risk factors associated with hepatitis B (HBV)-related hepatocellular carci-
noma (HCC) after resection remains unknown. An accurate risk score for HCC recurrence
is lacking.
Methods
We prospectively followed up 200 patients who underwent liver resection for HBV-related
HCC for at least 2 years. Demographic, biochemical, tumor, virological and anti-viral treat-
ment factors were analyzed to identify independent risk factors associated with recurrence
after resection and a risk score for HCC recurrence formulated.
Results
Two hundred patients (80%male) who underwent liver resection for HBV-related HCCwere
recruited. The median time of recurrence was 184 weeks (IQR 52–207 weeks) for the entire
cohort and 100 patients (50%) developed HCC recurrence. Stepwise Cox regression analy-
sis identified that one-month post resection HBV DNA >20,000 IU/mL (p = 0.019; relative risk
(RR) 1.67; 95% confidence interval (C.I.): 1.09–2.57), the presence of lymphovascular per-
meation (p<0.001; RR 2.69; 95%C.I.: 1.75–4.12), microsatellite lesions (p<0.001; RR 2.86;
95% C.I.: 1.82–4.51), and AFP >100ng/mL before resection (p = 0.021; RR 1.63; 95%C.I.:
1.08–2.47) were independently associated with HCC recurrence. Antiviral treatment before
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resection (p = 0.024; RR 0.1; 95% C.I.: 0.01–0.74) was independently associated with
reduced risk of HCC recurrence. A post-resection independent predictive score (PRIPS)
was derived and validated with sensitivity of 75.3% and 60.6% and specificity of 55.7% and
79.2%, to predict the 1- and 3-year risks for the HCC recurrence respectively with the hazard
ratio of 2.71 (95% C.I.: 2.12–3.48; p<0.001). The AUC for the 1- and 3-year prediction were
0.675 (95% C.I.: 0.6–0.78) and 0.746 (95% C.I.: 0.69–0.82) respectively.
Conclusion
Several tumor, virological and biochemical factors were associated with a higher cumulative
risk of HCC recurrence after resection. PRIPS was derived for more accurate risk assess-
ment. Regardless of the HBV DNA level, antiviral treatment should be given to patients
before resection to reduce the risk of recurrence.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide [1]. According
to cancer statistics released by the World Health Organization in 2008, HCC ranked the third
in the cancer mortality globally [2]. 78% of liver cancer is caused by either chronic hepatitis B
(CHB) or C infection [3]. CHB increases the risk by more than 20-fold. In Hong Kong, the
prevalence of CHB infection is approximately 8% [4]. Patients with CHB are estimated to expe-
rience HCC at a rate of 0.5% per year [5]. This rate increases to 2–3% per year in CHB patients
who already had cirrhosis [6], highlighting the importance and impact of hepatitis B virus
(HBV)-related HCC in the morbidity and mortality in high CHB prevalence population.
Investigators have identified several important viral factors, including high HBV viral load,
genotype C, core promoter mutation, pre-S deletions, and presence of T1653 and V1753 muta-
tions to be associated with increased risk of developing HCC in CHB patients [7–10]. For
patients who develop HCC, 20–30% are candidates for curative resection [11]. Nevertheless, the
intrahepatic recurrence rate after tumor resection is estimated to be>50% after 3 years [12].
In a previous relatively small-sized study, we have identified that age>60 years, tumor size
>5cm, α-fetoprotein (AFP) level>1000ng/ml and HBV viral load>2,000 IU/mL after tumor
resection, to be associated with increased cumulative risk of HCC recurrence [13]. We have
also completed a large-scale study using a statistical method to formulate a predictive score to
estimate the chance of occurrence of HCC as a time-dependent event during prospective fol-
low-up [14]. Based on these works, we conducted a large scale prospective-retrospective study
in patients who underwent resection for HBV-related HCC to identify independent risk factors
associated with recurrence of HCC and derived a novel post-resection independent predictive
score (PRIPS) for the development of recurrence. This novel risk score PRIPS would be useful
to predict the chance of recurrence of the HCC after resection and hence may provide impor-
tant guidance for subsequent surveillance strategy for HCC recurrence, and the development
of novel therapeutic strategies in the prevention of recurrence.
Patients and Methods
Study Design and Ethics
This study was designed in 2009 by the Departments of Medicine and Surgery, the University
of Hong Kong, Queen Mary Hospital. The study protocol conformed to the ethical guidelines
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of the 1975 Declaration of Helsinki and was approved by the institutional review board of the
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Patient’s selection
We prospectively recruited patients diagnosed to have HBV-related HCC who underwent
curative tumor resection between July 2009 and June 2011, in the Department of Surgery, the
University of Hong Kong, Queen Mary Hospital. All recruited patients were either at stage 0 or
A, according to the Barcelona Clinic Liver Cancer Staging upon resection. In addition, we
included the 72 patients who were recruited and followed up in the previous study [13]. Diag-
nosis of HBV-related HCC was based on imaging techniques including computerized tomogra-
phy (CT), hepatic angiography, magnetic resonance imaging and AFP level. All patients had
HCC confirmed by histological examination of the resected surgical specimens and HBV infec-
tion confirmed by positive hepatitis B surface antigen (HBsAg) in the serum. HCC recurrence
is defined as development of new intrahepatic lesions at least 6 months after the first HCC
resection. Patients with other concomitant liver diseases including hepatitis C or D viral infec-
tion, autoimmune hepatitis, Wilson’s disease, primary biliary cirrhosis, alcoholic liver disease,
fatty liver (diagnosed by ultrasonography) and extrahepatic metastasis diagnosed before resec-
tion were excluded from the study. Patients who suffered mortality from other causes besides
liver cause were censored at the last follow-up upon the time of death. Patients with other sig-
nificant co-morbidities were not recruited. Patient’s history of antiviral treatment given before
and within six months after resection was recorded.
Preoperative Investigations
Baseline demographic data including patient’s sex and age at first tumor resection were
recorded. Serum samples within 2 weeks before HCC resection were taken for liver function
tests and AFP. Abnormal alanine transaminase (ALT) is defined as a value of above the upper
limit of normal that is>53 IU/L for male and>37 IU/L for female, whereas abnormal AFP is
defined as>20ng/mL. Model for end stage liver disease (MELD) score and Child-Pugh score
for cirrhosis upon resection was calculated.
Viral Factors
Viral markers including HBsAg, hepatitis B e antigen (HBeAg) and antibody to HBeAg (anti-
HBe) were measured by the AxSYM immunoassay systems (Abbott Laboratories, Chicago, IL).
Specific HBV mutations including precore mutations (G1896A), core promoter mutations
(A1762T/G1764A), pre-S deletions, C1653T and T1753V mutations were determined by direct
sequencing in which the detailed methodologies were described in previous studies [15,16].
HBV genotypes were determined by phylogenetic comparison of the pre-S/S sequences with
reference HBV sequences in the NCBI GenBank. Serum samples were obtained at three time
points: before, and at one and six months after surgery for quantification of serum HBV DNA,
measured by the COBAS Taqman HBV Test (Roche Diagnostics, Branchburg, NJ) with a
lower limit of detection of 20 IU/mL.
Surgery and Tumor Factors
Surgery factors including blood loss during operation and techniques of hepatic resection (ana-
tomical or non-anatomical resection) were recorded. The resected tumors with its surrounding
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liver were examined for its histopathological features. The tumor size, resection margin, histo-
logical grade, presence of microsatellite formation and vascular permeation in the resected
tumor, together with the presence of cirrhosis in the non-tumorous liver were determined.
Follow-up
All patients were followed up at three monthly intervals with liver function test, AFP levels,
chest x-ray and helical contrast CT of the abdomen after resection to monitor for both intrahe-
patic and extrahepatic recurrence. All patients were follow-up for at least a period of 104 weeks
after resection.
Statistical analysis
Statistical analyses to identify risk factors for recurrence were performed using the SPSS 21.0
(IBM SPSS Statistics, IBM Corp, Somers, NY). Log-rank test was used to compare the cumula-
tive risks of development of HCC recurrence. Multivariable stepwise Cox regression model was
used to determine independent risk factors associated with HCC recurrence.
The PRIPS was then calculated as the weighted sum of those significant risk factors, with
weights taken as the estimated coefficients in multivariable Cox regression model. Prediction
accuracy of the risk score for 1- and 3-year HCC recurrence was assessed by the area under the
curve (AUC) in a time-dependent Receiver Operating Characteristic curve (ROC) analysis [17].
The corresponding 95% confidence intervals (CI) were obtained by bootstrapping of size 1000
with confidence limits taken as the 2.5th and 97.5th percentiles of the bootstrap samples. Tenta-
tive optimal cutoff values for predicting 1- and 3-year HCC recurrence were obtained as those
that maximized the Youden index, that was sensitivity and specificity—1, as derived from the
time-dependent ROC analysis. At the optimal cutoff values, sensitivity, specificity, predictive
values and likelihood ratios, as well as their corresponding 95% CIs were calculated. For practi-
cal reason, the final risk score was subtracted by the tentative optimal cutoff values such that the
optimal cutoff values were 0, i.e. a risk score0 predict HCC recurrence. Finally, we validated
the optimal cutoff values by using the leave-one-out cross-validation method [18]. The time-
dependent ROC and cross-validation analyses were performed in R 3.0.1 version [19].
Results
Two hundred patients with resection for HBV-related HCC who fulfilled the inclusion criteria
were recruited (Table 1). Seventy-two patients (36%) were recruited between June 2004 and
December 2006 from the previous study and the remaining 128 patients were recruited between
July 2009 and June 2011. The median age upon diagnosis of HCC was 56 years [interquartile
range (IQR) 49–65)] and 160 patients (80%) were male. Thirty-one patients (15.5%) were
HBeAg positive. The median follow-up time was 207 weeks (IQR 182–458 weeks) for patients
with no recurrence. By the end of the study, 100 patients (50%) developed HCC recurrence, of
which 53 patients died. For the entire cohort, the median time of recurrence was 184 weeks (3.5
years) (IQR 52–207 weeks) for the entire cohort of 200 patients. In comparison, no patients
died in the non-tumor recurrence group (p<0.001) (Table 1). Five patients died of pneumonia,
three patients died of stroke and 1 patient died of congestive heart failure. The remaining 44
patients died of HCC. None of the patients in the non-tumor recurrence group died.
All 200 patients had HBV DNA available before surgery for sequence analysis. One hundred
and seventy-three patients had sufficiently high HBV DNA levels for PCR amplification for
analysis of genotyping, pre-S deletions, core promoter, precore, C1653T and T1753V muta-
tions, in which 34.1% were genotype B and 65.9% were genotype C; 20.2% had pre-S deletions;
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82.1% had core promoter mutations; 40% had precore mutations; 19.1% had C1653T muta-
tions and 31.2% had T1753V mutations.
Demographic Factors and HCC Recurrence
Patients with age>60 years upon diagnosis and gender were not associated with HCC recur-
rence (Table 1). Recurrence was strongly associated with death (p<0.001).
Table 1. Virological and clinic-pathological factors of the 200 patients in cumulative recurrence of hepatocellular carcinoma after resection by log-
rank test.
Tumor Recurrence (n = 100) No Tumor Recurrence (n = 100) p Value
Demographic Factors
Median age (IQR) years 56 (49–66) 56 (49.3–63) 0.26
Age >60 years 38% 34% 0.73
Male 79% 81% 0.77
Biochemical Factors
AFP >100ng/mL 48% 35% 0.01
MELD score (IQR) 6.4 (4.95–8.20) 6.5 (5.1–8.28) 0.90
Child-Pugh score A 96% 96% 1.00
Cbild-Pugh score B 4% 4% 1.00
Surgery Factors
Blood loss (L) 0.58 (0.2–1.2) 0.45 (0.15–1.0) 0.34
Anatomical resection 85% 89% 0.40
Tumor Factors
BCLC stage 0 12% 14% 0.67
BCLC stage A 88% 86% 0.67
Tumor number = 1 92% 93% 0.72
Tumor number = 2 7% 5%
Tumor number = 3 1% 2%
Tumor size >3cm 72% 57% 0.026
Poor differentiated tumor 88% 62% <0.001
Presence of microsatellite lesions 31% 6% <0.001
Lymphovascular permeation 52% 19% <0.001
Cirrhosis 60% 54% 0.47
Viral Factors
Pre-resection HBV DNA >20,000 IU/mL 66% 44% 0.002
1 month post-resection HBV DNA >20,000 IU/mL 56% 34% 0.002
6 months post-resection HBV DNA >20,000Iu/mL 37% 23% 0.031
Pre-S deletion 18% 17% 0.93
Positive eAg 16% 15% 0.78
C1653T 23% 10% 0.042
T1753V 29% 25% 0.87
Genotype C 64% 50% 0.39
Presence of core promoter mutation 82% 60% 0.032
Presence of precore mutation 33% 31% 0.95
Antiviral Treatment
Antiviral treatment before resection 1% 23% <0.001
Antiviral treatment after resection 43% 49% 0.40
Outcome
Death 53% 0% <0.001
doi:10.1371/journal.pone.0148493.t001
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Biochemical Factors and HCC Recurrence
AFP>100ng/mL (p = 0.01) at the time of resection was associated with a higher cumulative
risk of developing HCC recurrence after resection (Table 1). There was no difference in the
MELD and Child-Pugh scores upon resection between the two groups.
Surgery Factors and HCC Recurrence
There was no difference in blood loss and resection techniques between the two groups
(Table 1).
Tumor Factors and HCC recurrence
Resected tumor size>3cm (p = 0.026); moderate or poor differentiated HCC (p<0.001), the
presence of lymphovascular permeation (p<0.001) and the presence of microsatellite lesions
(p<0.001) at the time of resection were associated with a higher cumulative risk of developing
HCC recurrence after resection (Table 1). 114 (57%) patients were diagnosed to have underly-
ing cirrhosis, which was not associated with recurrence. 26 (13%) patients have Barcelona-
Clinic Liver Cancer (BCLC) stage 0 and 174 (87%) patients have BCLC stage A diseases respec-
tively upon diagnosis. 185 patients (92.5%) have single lesion, 12 patients (6%) have two lesions
and 3 patients (1.5%) have three lesions respectively. There was no difference in BCLC staging
and number of tumors between the two groups.
Virological Factors and HCC Recurrence
Despite only 31 patients (15.5%) were HBeAg positive, the median HBV DNA at the time of
resection remained high at 5.4x104 IU/mL (IQR 2.4x102–1.1x105 IU/mL). Patients with pre-
resection HBV DNA>20,000 IU/mL (p = 0.002), 1 and 6 months post-resection HBV DNA
>20,000 IU/mL (p = 0.001 and p = 0.02 respectively), the presence of core promoter
(p = 0.032) and C1653T (p = 0.042) mutations was associated with a higher cumulative risk of
developing HCC recurrence after resection (Table 1). Genotypes, pre-S deletion, precore and
T1753V mutations were not associated with cumulative risk of developing HCC recurrence
after resection.
Antiviral Treatment and HCC Recurrence
Twenty-four and 92 patients received antiviral treatment before and within 6 months after
resection respectively. Out of the 24 patients who received antiviral treatment before resection,
8 patients (33.3%) had HBV DNA>20,000 IU/mL before resection and 22 patients (91.7%)
had undetectable HBV DNA at 6 months after resection. Only 1/24 patients (4.2%) and none
of the 8 patients with HBV DNA>20,000 IU/mL developed HCC recurrence. Patients who
received antiviral treatment before resection were associated with significantly lower cumula-
tive risk of recurrence compared to patients with no anti-viral treatment (p<0.001) (Table 1).
For those patients who received antiviral treatment within 6 months after resection, 62/92
(67.4%) had HBV DNA>20000 IU/mL before resection, 36/92 (39.1%) had undetectable HBV
DNA at 6 months after resection and 43/92 (46.7%) developed HCC recurrence.
Independent Risk Factors for HCC Recurrence
Significant factors associated with higher cumulative risk of tumor recurrence by univariable
analyses included AFP>100 ng/mL at the time of resection; tumor size>3cm; poor tumor dif-
ferentiation; the presence of lymphovascular permeation; the presence of microsatellite lesions;
HBV viral load>20,000 IU/mL pre-resection, at 1 and 6 months post resection; the presence
Risk Factors and PRIP Score for Recurrence of HBV HCC Post Resection
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of core promoter and C1653T mutations; patients with antiviral treatment before resection
(Table 1) were identified. These data were entered into multivariate analysis (Table 2). Stepwise
Cox regression analysis identified that one-month post-resection HBV DNA>20,000 IU/mL
(p = 0.019; relative risk (RR) 1.67; 95% C.I.: 1.09–2.57) (Fig 1), the presence of lymphovascular
permeation (p<0.001; RR 2.69; 95% C.I.: 1.75–4.12) (Fig 2), the presence of microsatellite
lesions (p<0.001; RR 2.86; 95% C.I.: 1.82–4.51) (Fig 3), and AFP>100ng/mL before resection
(p = 0.021; RR 1.63; 95% C.I.: 1.08–2.47) (Fig 4) were independently associated with HCC
recurrence (Table 2). Antiviral treatment before resection (p = 0.024; RR 0.1; 95% C.I.: 0.01–
0.74) (Fig 5) was independently associated with reduced risk of HCC recurrence.
Post-resection Independent Predictive Score (PRIPS)
The derived PRIPS after subtracting the tentative optimal score was formulated as [0.43 
AFP<100ng/mL before resection + 1.01  presence of lymphovascular permeation + 1.03 
Table 2. Multivariable analysis of independent factors associated with tumor recurrence.




Lymphovascular permeation 2.69 (1.75–4.12) <0.001
Presence of microsatellite lesions 2.86 (1.82–4.51) <0.001
One month post resection HBV DNA >20,000 IU/
mL
1.67 (1.09–2.57) 0.019
Antiviral treatment before resection 0.10 (0.01–0.74) 0.024
AFP >100ng/mL before resection 1.63 (1.08–2.47) 0.021
doi:10.1371/journal.pone.0148493.t002
Fig 1. Cumulative tumor recurrence between patients with or without one month post-resection HBV
DNA >20,000 IU/mL.
doi:10.1371/journal.pone.0148493.g001
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presence of microsatellite lesions + 0.45  one-month post-resection HBV DNA>20,000 IU/
mL—2.90  antiviral treatment before resection– 0.45, with each variable either as presence = 1
or absence = 0]. The relative risk of the PRIPS for HCC recurrence was 2.71 (95% C.I.: 2.12–
3.48, p<0.001). The AUC were 0.675 (95% C.I.: 0.6–0.78) and 0.746 (95% C.I.: 0.69–0.82) for 1-
and 3- year prediction respectively. The optimal cut-off of 0 had good sensitivity of 75.3% and
60.6% respectively and specificity of 55.7% and 79.2% respectively, to predict the 1- and 3-year
risks for the HCC recurrence after resection (Table 3; Fig 6). In the leave-one-out validation
analysis, all accuracy measures highly resembled to those obtained on the total sample, showing
good accuracy but with generally wider confidence intervals. The relative risk of the PRIPS by
the leave-one-out cross validation was 2.05 (95% C.I.: 1.63–2.57, p<0.001).
Discussion
This is the first prospective study to comprehensively investigate demographic, biochemical,
tumor, virological and antiviral treatment for risk factors associated with recurrence of HCC
after resection. In this study, the median time to HCC recurrence post-resection was 184
weeks, which is comparable to the 34 months as reported in the study by Shah SA et al [20].
and longer than the 24 and 11.9 months reported in the study by Cha C et al. and Kumar AM
et al. respectively [21,22]. The median follow-up time of 207 weeks was also much longer than
the 75 weeks in our previous study [13]. We have included additional risk factors namely, HBV
DNA level before and after HCC resection, pre-S deletions, C1653T and T1753V mutations,
MELD and Child-Pugh scores, and surgical factors including blood loss and anatomical resec-
tion in the current study [23]. Baseline demographics including male predominance and
median age of diagnosis were similar in both studies. However, age>60 years was no longer
associated with recurrence. The ‘age factor’ associated with recurrence after resection remains
Fig 2. Cumulative tumor recurrence between patients with or without lymphovascular permeation.
doi:10.1371/journal.pone.0148493.g002
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controversial. A recent study found younger age was associated with more aggressive disease,
shorter survival and higher recurrence rate [24], another study suggested otherwise [25].
Biochemical and histopathological are strongly associated with tumor recurrence post-
resection. In this study, AFP>100ng/mL before resection and lymphovascular permeation
were independently associated with recurrence [13,23]. Similar pathological risk factors pre-
dicting recurrence patterns were found in a recent study.[26]. High serum AFP level suggests
tumor vascular invasion and was associated with poor recurrence-free survival [27]. Cirrhosis
was not found to be associated with recurrence in both of our studies [13]. The cirrhosis factor
remained controversial. Early studies have suggested that cirrhosis associated with recurrence
[28,29], whereas a more recent study in a Western cohort suggested that non-cirrhotic patients
were associated with higher recurrence rate [30]. Biochemical factors including MELD and
Child-Pugh scores, surgical factors including blood loss and anatomical resection were not
associated with recurrence in our study.
High HBV viral load was found to be strongly associated with recurrence after various inter-
ventions including liver resection, transcatheter arterial embolization and radiofrequency abla-
tion [13,31–35]. Ongoing HBV viral replication can induce active hepatitis, oxidative stress,
fibrosis and subsequent tumor recurrence. Integration of the oncogenic HBV DNA into the
host hepatocytes can alter transforming growth factor-beta1 and alpha (2)-macroglobulin pro-
duction and inhibit the effect of tumor suppressor genes, resulting in uncontrolled cellular pro-
liferation and malignancy [36]. Patients with high HBV viral load after the resection will
therefore be more prone to recurrence. There is also an increased risk of multicentric recurrent
tumors in the liver remnant and subsequent recurrence.
Fig 3. Cumulative tumor recurrence between patients with or without microsatellite lesions.
doi:10.1371/journal.pone.0148493.g003
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Recent meta-analysis demonstrated that the presence of pre-S, C1653T, T1753V, and core
promoter mutations are associated with an increased risk of HCC [37]. It is likely that these
mutations are associated with enhanced viral replication, resulting in hepatocarcinogenesis.
One study even suggested the presence of A1762T/G1764A double mutations might act in syn-
ergy with C1653T to increase the risk of HCC in patients with HBV genotype C2 infection
[38]. Nevertheless, the presence of genotype C and pre-S deletion were not associated with
recurrence in the current study. This concurred with findings from another recent study,
which suggested postoperative recurrence, or survival period may not be predominantly
affected by the genomic changes [24], but more closely associated with tumor characteristics.
The Cox regression model identified the presence of lymphovascular permeation, the pres-
ence of microsatellite lesions, one month post-resection HBV DNA>20,000 IU/mL, no antivi-
ral treatment before resection and AFP>100ng/mL as the 5 independent factors associated
with higher cumulative risk of tumor recurrence after resection. Among these 5 risk factors,
antiviral treatment before or after resection was the only amenable factor. Results from small
studies regarding the effectiveness of nucleoside analogues in HCC recurrence have been con-
troversial [39,40], whereas a large study of by Chan et al. [41], reported that the 5-year tumor
free survival rate in antiviral group was significantly higher than the control. More recently a
large cohort study from Taiwan [42] demonstrated that the 6-year cumulative recurrence and
the overall mortality were significantly lower with nucleoside analogue use. The likely mecha-
nism was that antiviral treatment decreased viral load, thereby reducing the risk of inflamma-
tion, fibrosis and subsequently recurrence of the HCC. Another study showed that patients
with low or undetectable HBV DNA (<2,000 IU/mL) and not on antiviral agents are still at
risk of developing HCC [43]. Therefore, pre-surgery HBV DNA and antiviral agent before sur-
gery remain important factors in predicting HCC recurrence. Antiviral treatment should be
Fig 4. Cumulative tumor recurrence between patients with or without AFP >100ng/mL before
resection.
doi:10.1371/journal.pone.0148493.g004
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Fig 5. Cumulative tumor recurrence between patients with or without antiviral treatment before
resection.
doi:10.1371/journal.pone.0148493.g005
Table 3. Optimal cut-off values bymaximizing Youden index and their accuracies for the PRIPS derived fromwhole study population and validated
with leave-one-out cross-validation.
1-year prediction 3-year prediction
Value 95% CI Value 95% CI
Total study population
Optimal cut-off 0 0
Sensitivity 75.3 36.6, 85.5 60.6 46.0, 76.9
Speciﬁcity 55.7 46.1, 90.4 79.2 65.2, 76.9
Positive predictive value 34.9 31.0, 59.2 72.1 64.0, 87.0
Negative predictive value 87.7 81.4, 92.3 69.4 64.2, 77.3
Positive likelihood ratio 1.70 1.42, 4.60 2.91 2.01, 7.56
Negative likelihood ratio 0.44 0.27, 0.72 0.50 0.33, 0.63
Leave-one-out cross-validation
Sensitivity 82.5 51.5, 86.3 77.2 55.0, 80.3
Speciﬁcity 47.3 47.2, 71.1 55.6 54.2, 83.0
Positive predictive value 33.1 28.4, 42.5 60.7 57.5, 76.8
Negative predictive value 89.5 79.9, 92.6 73.4 63.2, 79.1
Positive likelihood ratio 1.57 1.25, 2.34 1.74 1.53, 3.73
Negative likelihood ratio 0.37 0.25, 0.80 0.41 0.30, 0.66
doi:10.1371/journal.pone.0148493.t003
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given to all patients with low or undetectable HBV DNA level before resection. For patients in
resource poor countries, antiviral treatment could be prioritized according to the PRIPS.
The PRIPS was derived from the 5 independent risk factors including viral, pathological
and biochemical factors. This allows a more comprehensive assessment compared to other pro-
posed scoring system in predicting HCC recurrence, which either focuses on pathological or
biochemical factors. El-Assal ON et al. [44] used an invasiveness score based on 6 pathological
parameters, Roayaie S et al. [45] used a system of microvascular invasion, Pan QX et al. [46]
used the Glasgow Prognostic Score based on C-reactive protein and albumin level, Yamamura
K et al. [47] used the neutrophil to lymphocyte ratio (NLR) prognostic score, Zhao WH et al.
[48] used the pre-surgery Cancer of the Liver Italian Program (CLIP) score and Shim JH et al.
[49] used the preoperative AFP<20ng/mL to predict HCC recurrence. Only the study by Shim
JH et al. provided an AUC analysis of the performance of their AFP model to compare with
our PRIPS model. The PRIPS model AUC for the 1- and 3-year predictions were 0.67 and 0.75
respectively, which is better than the AFP model with an AUC of 0.53 and 0.49 respectively. In
addition, we have compared the AUC of the PRIPS against the CLIP score using the current
cohort. The AUC of the CLIP score for 1- and 3-year prediction were 0.509 and 0.497, which
was lower than the AUROC of the PRIPS (AUROC of PRIPS for 1-yr = 0.675 and 3-ys = 0.746;
p-value0.001).
This score was validated by the stringent leave-one out statistical analysis with high sensitiv-
ity and specificity of 82.5% and 47.3% respectively for the prediction at 1 year. There was a
slight change in sensitivity and specificity of 77.2% and 55.6% for the prediction at 3 years.
This was the first derived risk score to predict HCC recurrence after resection with integration
of viral, biochemical and histopathological factors. Using this novel recurrence risk score, clini-
cians can predict and subsequently reduce the risk of recurrence by starting patients on antivi-
ral treatment before or even after tumor resection. The estimated risk for 1- and 3-year HCC
recurrence in patients with 4 risk factors of lymphovascular permeation, microsatellite lesions,
one month post-resection HBV DNA>20,000 IU/mL and AFP>100ng/mL would be 80%
and 99% respectively. By commencing antiviral treatment before resection, the 1-year risk
would be reduced to 8% and the 3-year risk would be reduced to 24%.
There were several limitations of this study. Firstly, We were unable to perform external val-
idation to compare PRIPS with other prediction models with a different population at this
stage. We plan to perform external validation in future prospective study. Secondly, subjects
were not entirely prospectively recruited. Thirdly, there has been no accuracy estimation
Fig 6. Chance of recurrence of hepatocellular carcinoma at 1 and 3 years according to the different
values of the PRIPS.
doi:10.1371/journal.pone.0148493.g006
Risk Factors and PRIP Score for Recurrence of HBV HCC Post Resection
PLOS ONE | DOI:10.1371/journal.pone.0148493 February 22, 2016 12 / 15
method that can be correct in all situations [50,51]. Leave-one-out is almost unbiased and was
chosen to provide accuracy estimates of minimum bias [52], rather than bootstrapping. Boot-
strapping has been shown to have large bias in its estimates, as illustrated in some real situa-
tions [53]. However, it is an expensive procedure with high sample size requirement. Hence,
external validation using independent dataset would be necessary to confirm the accuracy of
the proposed risk prediction model.
In conclusion, the present large-scale study had identified several tumor, virological and
biochemical factors associated with higher cumulative risks of HCC recurrence after resection.
In addition, a novel risk score PRIPS was derived to predict the risk of HCC recurrence after
resection. Regardless of the HBV DNA level, antiviral treatment should be given to patients
before resection to reduce the risk of recurrence.
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